Gilead Follows Up Wall St. Hot Streak with Big Money Alliances
Executive SummaryAn enviable cash position gives Gilead the luxury of making agreements like licensing exclusive ex-US rights to Vistide to Pharmacia & Upjohn. They also entered a broader deal with Hoffmann-La Roche surrounding its neuraminidase inhibitor program for influenza treatment.
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.